ArticleIrish journal of medical science2026
The cost of cancer care: how much would you pay for your drugs? Patient and oncology professional stakeholder opinions in Ireland.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAn incremental cost-effectiveness ratio (ICER) threshold of €45,000/Quality-Adjusted-Life-Year (QALY) is used in the assessment of new drugs in Ireland. We assessed stakeholder perceptions of this, and willingness-to-pay for new drugs.
methodsWe surveyed oncology patients (n = 125), oncologists, pharmacists, and nurses (n = 61, April-July 2023). Participants reviewed 9 hypothetical scenarios, including costs and survival outcomes with 'current treatments', alongside information about a 'better' drug, and estimated how much the state should pay (5 scenarios).
resultsIn most cases, willingness-to-pay exceeded current thresholds. Staff thresholds (overall median €52,264/QALY, IQR €13,671 - 108,000) were more conservative than patients (€90,857/QALY, €13,671 - 216,000) for almost all scenarios. Both staff and patients would pay more for overall survival benefit than quality of life benefit. Providing more biographical information increased patient thresholds (€224,571, IQR €90,857-€558,857) but not staff. Patient median threshold was €816,000 per recurrence prevented (IQR €240,000-1,776,000).
conclusionsWe demonstrate stakeholder desire for an increase in spending thresholds.
Indexed as
Identifiers
42250039What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.